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Abstract Chromosomal instability is a hallmark of human
cancers and is closely linked to tumorigenesis. The prognostic
value of molecular signatures of chromosomal instability
(CIN) has been validated in various cancers. However, few
studies have examined the relationship between CIN and
glioma. Histone deacetylases (HDACs) regulate chromosome
structure and are linked to the loss of genomic integrity in
cancer cells. In this study, the prognostic value of HDAC4
expression and its association with markers of CIN were
investigated by analyzing data from our own and four other
large sample databases. The results showed that HDAC4
expression is downregulated in high- as compared to low-
grade glioma and is associated with a favorable clinical out-
come. HDAC4 expression and CIN were closely related in
glioma from both functional and statistical standpoints.
Moreover, the predictive value of the O-6-methylguanine-
DNA methyltransferase (MGMT) promoter methylation sta-
tus—a widely used glioma marker—was refined by HDAC4
expression level, which was significantly related to CIN in our
study. In conclusion, we propose that HDAC4 expression, a
prognostic and CIN marker, enhances the predictive value of
MGMT promoter methylation status for identifying patients
who will most benefit from radiochemotherapy.
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Introduction
Glioma is the most common type of primary central ner-
vous system (CNS) tumor and a leading cause of tumor-
related mortality. Despite major advances in therapy over
the past decades, the clinical outcome for most patients
remains poor. This is especially true for glioblastoma
(GBM), the most malignant grade of glioma, which has a
median survival of 14.6 months and a 2-year survival rate
of 5–10 % even after aggressive therapy [1]. As a major
form of genomic instability, chromosomal instability (CIN)
is a critical event in early stages of tumorigenesis and,
when compounded, leads to the transformation of normal
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cells into cancer cells [2]. Various types of CIN have
been detected in glioma, including mutations, loss of het-
erozygosity, and copy number aberrations [3–6]. Several
studies have reported that CIN can affect sensitivity to
chemotherapy and consequently the prognosis of glioma
patients [7, 8].
A close association between CIN and histone acetylation
has been demonstrated [9–11]. Central to histone acetylation
are histone deacetylases (HDACs), which maintain genomic
integrity by targeting histone and non-histone proteins and
thereby regulating DNA repair mechanisms [12]. A total of
18 human HDACs, classified into four groups, have been
identified. As a member of group II HDACs, HDAC4 is
closely linked to many disease processes—including cancer,
leukemia, diabetes, infection, and cardiac disease [13–18]—
and is also highly expressed in the brain where it plays an
important role in brain functioning [19–22].
Epigenetic silencing of the O-6-methylguanine-DNA
methyltransferase (MGMT) gene by promoter methylation is
associated with prolonged survival and sensitivity to che-
motherapeutic alkylating agents in GBM patients undergo-
ing standard treatment [23, 24]. The beneficial effects of
combined radiochemotherapy vary significantly between
GBM patients, even for those with a methylated MGMT
promoter [25]. This suggests that while important, MGMT
promoter methylation is not the sole factor determining
clinical outcome, and highlights the need for evaluating
patients based on other factors; for instance, CIN combined
with MGMT promoter methylation status may provide more
accurate information for predicting disease outcome.
CIN is defined as the gain or loss of whole or fractions
of chromosomes, and is associated with tumorigenesis,
disease prognosis, and acquisition of multi-drug resistance
in various cancers, including breast cancer, melanoma, and
lymphoma [26–32]. High throughput gene expression
profiling approaches have established a reasonable link
between the expression of specific genes and the degree of
CIN in multiple cancers. Carter et al. developed compu-
tational methods to measure the ‘‘CIN score’’ for 10,151
genes, which indicates the correlation between each gene
and the CIN degree in tumor samples [30]. Based on the
‘‘CIN score’’, the top ranked genes are chosen for forming
the CIN signature, which was represented by CIN25 score
(Further backgrounds of CIN signature and CIN25 score
are shown in the Supplementary Text) [30]. The CIN sig-
nature, comprising a specific set of genes that are critical
for maintaining genomic integrity, is significantly higher in
metastatic foci, and stratifies patients according to clinical
outcome in various cancers, suggesting that these genes are
responsible for a more aggressive cancer phenotype [30,
33]. However, as it consists of multiple genes, the CIN
signature is too complex to be suitable for routine clinical
application. The present study investigated whether
HDAC4 expression can serve as an alternative marker for
assessing the degree of CIN and, in combination with
MGMT promoter status, predict the outcome of patients.
Materials and methods
Patients and samples
A total of 539 glioma specimens from the Chinese Glioma
Genome Atlas (CGGA) that were contiguously collected at
multiple centers were used in this study. Tumor tissue
samples were obtained by surgical resection prior to radio
and/or chemotherapy, flash-frozen in liquid nitrogen, and
stored at -80 C until nucleic acid extraction. The study
protocol was approved by the ethics committees of par-
ticipating hospitals. Each sample was diagnosed and
independently confirmed histopathologically at the
Department of Pathology according to the 2007 WHO
classification system of CNS tumors by two experienced
neuropathologists. Clinical data, including age, sex, pre-
operative KPS score, adjuvant radiation and chemotherapy,
and the recorded date of disease progression or death were
obtained from medical records.
Data on mRNA expression were obtained by whole tran-
scriptome sequencing (N = 325) and whole-genome mRNA
expression microarray (N = 299) from the CGGA, and the
following four datasets were used for validation: the Cancer
Genome Atlas (http://cancergenome.nih.gov); Repository





Evaluation of MGMT promoter methylation by DNA
pyrosequencing
MGMT promoter methylation status was detected by DNA
pyrosequencing as previously described [34, 35]. Bisulfite
DNA modification was performed using the EpiTect Kit
(Qiagen). The following primers were used to amplify the
MGMT promoter region: 50-GTTTYGGATATGTTGGG
ATA-30 (forward) and 50-biotin-ACCCAAACACTCACCA
AATC-30 (reverse). The PCR analysis was performed in
duplicate in a 40-ll reaction volume containing 0.5 ll each
primer (using a 10-lM working solution), 4 ll 10 9 buf-
fer, 3.2 ll of 2.5 lM dNTP, 2.5 U hotstart Taq (Takara
Bio, Madison, WI, USA), and 2 ll of 10 lM bisulphite-
treated DNA. The reaction conditions were: 95 C for
3 min; 40 cycles of 95 C for 15 s, 52 C for 30 s, and
72 C for 30 s; and 72 C for 5 min (ABI 9700; Applied
Biosystems, Foster City, CA, USA). DNA was purified
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from total PCR products using QIAamp DNA Mini Kit
(Qiagen, Valencia, CA, USA) and subjected to pyrose-
quencing (PyroMark Q96 ID System; Qiagen) using the
primer 50-GGATATGTTGGGATAGT-30 in accordance
with the manufacturer’s instructions. The obtained meth-
ylation values were averaged across the seven tested CpG
loci within the MGMT promoter. Samples were considered
as having a methylated MGMT promoter if the average
methylation was C10 %.
Survival analysis
To assess the prognostic value of HDAC4 expression in
glioma, a survival analysis for each tumor grade was per-
formed based on expression level. The combined effect of
MGMT promoter methylation status and HDAC4 expres-
sion was then assessed in GBM. Patients receiving radio-
chemotherapy were stratified into two groups according to
MGMT status, and further classified into four subgroups
based on HDAC4 expression level; the statistical signifi-
cance was determined by the log-rank test.
CIN25 score based on 25 genes was calculated as the
sum of the expression levels of each signature gene in a
patient [30]. Dichotomization was performed for each
tumor grade to classify patients into two groups based on
the median signature score. Patients who received radio-
chemotherapy were then stratified into four subgroups
based on MGMT status and CIN25 score to study the
combined effect of these parameters in GBM, and a sur-
vival analysis was carried out.
Gene ontology (GO) analysis and gene set enrichment
analysis (GSEA)
A Pearson correlation analysis was performed across gli-
oma grades to identify genes that are significantly related to
HDAC4. GO analysis was performed using the DAVID
(http://david.abcc.ncifcrf.gov/home.jsp) [36]. To obtain
more information about the relationship between CIN25
score and HDAC4, GSEA (http://www.broadinstitute.org/
gsea/index.jsp) was performed as previously described to
determine whether the identified set of genes showed sta-
tistically significant differences between the two biological
states [37].
Statistical analysis
SPSS software and GraphPad Prism 6 were used for sta-
tistical analyses. The differences in HDAC4 expression and
CIN25 score between groups were compared using Stu-
dent’s t and v2 tests. A dichotomization based on the median
HDAC4 expression level and CIN25 score was carried out
for the survival analysis. Overall survival (OS) was
calculated from the date of diagnosis until death or the end
of follow-up. Progression-free survival (PFS) was defined
as the time between the diagnosis and the first unequivocal
clinical or radiological sign of disease progress. Kaplan–
Meier survival analyses for OS and PFS were performed
and compared with the log-rank test. A Pearson correlation
analysis was used to test the correlation between CIN25
score and HDAC4 expression. Statistical significance was
defined as a two-tailed P value \ 0.05.
Results
HDAC4 expression is significantly associated
with progressive malignancy in glioma
To test the relationship between HDAC4 expression and
tumor grade, patients were stratified into low or high
expression groups according to the median value for
HDAC4 expression in each database. The percentage of
samples with low expression increased with progressive
malignancy (P \ 0.001; v2 test) (Table S1). This correla-
tion between HDAC4 expression and tumor grade was
studied in CGGA and three validation sets (Fig. 1a–d)
showing that HDAC4 expression differed among various
grades and was downregulated for higher grades. Based on
these results, we propose that low HDAC4 expression is a
characteristic of high-grade glioma.
Highly expressed HDAC4 prolongs survival
and strengthens the predictive value of MGMT
promoter methylation
To evaluate the prognostic value of HDAC4 expression in
glioma, dichotomization was applied in every grade to
separate samples into two groups based on HDAC4
expression level. Kaplan–Meier survival curves in CGGA
and three validation sets showed that HDAC4 overexpres-
sion conferred longer OS (Fig. 2a–j) and PFS (Fig. S1a–c)
in each grade. When both radiochemotherapy and MGMT
promoter methylation status were considered, 55 GBM
patients were included in the assessment of the prognostic
value of HDAC4 expression combined with MGMT pro-
moter methylation status. Patients were assigned to four
subgroups according to their MGMT status and HDAC4
expression level, as described above. Notably, OS varied
significantly among the four subgroups (P = 0.027;
Fig. 2k). Among patients with a methylated MGMT pro-
moter, those with higher HDAC4 expression had a median
OS of 669 days, which was significantly longer than that of
patients with low HDAC4 expression or with a non-meth-
ylated MGMT promoter (Fig. 2k). There were no other
differences among the three subgroups. A similar analysis
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was carried out in GBM patients who had received stan-
dard radiation combined chemotherapy in the TCGA
database, and the results confirmed that patients with
MGMT promoter methylation and high HDAC4 expression
had a significantly longer OS than other patients (Fig. 2l).
HDAC4 expression is closely correlated with chromatin
structure
A Pearson correlation analysis was conducted to identify
genes whose expression is correlated with that of HDAC4. A
total of 4,794 genes were significantly correlated (3,262 genes
with R \ - 0.3 and 1,532 genes with R [ 0.3; P \ 0.001).
Positively correlated genes with a P value\ 1e-10 were used
for the GO analysis, which revealed ten processes mostly
related to chromatin organization and histone modification.
These results confirm that HDAC4 is critical for regulating
chromosome structure (Table 1).
A high CIN25 score is associated with progressive
malignancy, poor prognosis, and chemotherapy
resistance in glioma
The CIN25 score was used as a marker of CIN. Based on
the median score across tumor grades, patients were
stratified into low and high score groups. Patients with high
scores has greater representation among higher tumor
grades (P \ 0.001; v2 test) (Table S2). Analysis of data
from the CGGA and two validation databases (Student’s t
test) (Fig. 3a–c) showed that CIN25 scores increased as a
function of glioma grade and was highest in the most
malignant GBM, indicating that CIN is tightly associated
with glioma progression.
The prognostic value of the CIN25 score in glioma was
next evaluated across three independent databases. The OS
and PFS showed a notable reduction for patients with a high
as compared to a low CIN25 score (Fig. 3d–f, Fig. S2, S3). In
52 GBM patients who received post-operative radiochemo-
therapy, MGMT promoter methylation status and CIN25
score were incorporated into the stratification; in this case,
the OS differed significantly among subgroups (P = 0.025;
Fig. 3g). Patients with MGMT promoter methylation and
lower CIN25 score had a longer OS than the other three
subgroups. A significant difference in clinical outcome was
detected in the MGMT promoter methylation group, dem-
onstrating that a low CIN25 score was associated with better
prognosis than a high CIN25 score (P = 0.046; Fig. 3g).
When the relationship between CIN25 score and response to
chemotherapy in GBM was analyzed, patients with a lower
CIN25 score who received radiochemotherapy had longer
Fig. 1 HDAC4 expression is
negatively correlated with
tumor grade. The association
between HDAC4 expression
level and grade II, III, and IV
glioma was evaluated in the
CGGA (a) and three other
validation sets (b–d)
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survival times than those who received radiotherapy alone
(P \ 0.001, Fig. 3h). However, there was no difference
between these two treatment conditions among patients with
high CIN25 scores (Fig. 3i), suggesting that the poor prog-
nosis observed in these patients may be due to the acquisition
of chemotherapy resistance.
Fig. 2 Higher HDAC4 expression is associated with longer OS in the
CGGA, REMBRANDT, GSE16011, and TCGA databases (a–j).
Survival analysis according to MGMT promoter status combined with
HDAC4 expression was performed with data from the CGGA (k) and
TCGA (l). Patients whose tumors had a methylated MGMT promoter
and a higher expression of HDAC4 had the best prognosis
Table 1 Gene ontology (GO)
terms for HDAC4-associated
genes
Term Count P value Fold enrichment
GO:0006325 * chromatin organization 27 0.04587 1.47075
GO:0016568 * chromatin modification 21 0.04497 1.57811
GO:0016569 * covalent chromatin modification 14 0.00810 2.28784
GO:0016570 * histone modification 14 0.00621 2.36285
GO:0016573 * histone acetylation 10 0.00043 4.28970
GO:0043966 * histone H3 acetylation 7 0.00127 5.54361
GO:0043983 * histone H4-K12 acetylation 3 0.03092 10.29528
GO:0043982 * histone H4-K8 acetylation 3 0.03092 10.29528
GO:0043984 * histone H4-K16 acetylation 3 0.03092 10.29528
GO:0043981 * histone H4-K5 acetylation 3 0.03092 10.29528
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CIN signature is strongly associated with HDAC4
expression in glioma
A correlation analysis revealed that HDAC4 expression
was significantly correlated with CIN25 score (Fig. 4a,
P \ 0.001, R = - 0.366), which was confirmed by
data from the REMBRANDT and GSE16011 datasets
(P \ 0.001, R = - 0.461 and P \ 0.001, R = - 0.309,
respectively; Fig. 4b, c). This suggests a significant rela-
tionship between HDAC4 expression and CIN in glioma.
The GSEA was used to test whether HDAC4 expression is
correlated with genes contributing to the CIN25 score.
Samples were listed in order of increasing HDAC4
expression. The results indicate that CIN25 genes were
significantly enriched in samples with low HDAC4
expression, whereas high HDAC4 expression was not
correlated with any of these genes (NES = 1.5306281,
P = 0.027; Fig. 4d).
Discussion
The high prevalence, mortality, and risk of post-treatment
complications associated with glioma make it one of most
challenging diseases affecting humans. Moreover, patients
with the same diagnosis may experience vastly different
clinical outcomes even after undergoing the same treat-
ment. This heterogeneity highlights the limitations of a
grading system based purely on pathological characteriza-
tion. As a feature of most human cancers, CIN—which has
a high degree of heterogeneity among tumor cells and
involves a complex network of molecular interactions
rather than a single signaling pathway [38]—may better
reflect glioma severity and offer a more accurate measure
for predicting disease prognosis.
HDACs are the main regulators of histone acetylation,
which has been implicated in CIN. As a member of group
II HDACs, HDAC4 is highly expressed in the brain and
Fig. 3 Correlation between CIN25 score and glioma malignancy.
CIN, as measured by the CIN25 score, was analyzed with respect to
tumor grade (II–IV) in the CGGA (a) and two validation sets (b, c). A
high CIN25 score was associated with shorter OS (d–f) in the CGGA.
A survival analysis for MGMT promoter status combined with CIN25
score was performed in the CGGA (g). Sensitivity to chemotherapy
was assessed in GBM patients. Patients with a low CIN25 score
receiving radiochemotherapy had better OS than those receiving
radiotherapy alone (h); no differences between treatment groups were
observed among patients with a high CIN25 score (i)
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involved in various functions including learning and
memory, behavior, and neuronal survival [19–21, 39, 40].
We propose that HDAC4 expression is closely associated
with glioma grade and prognosis, with a lower HDAC4
expression significantly associated with progressive
malignancy and unfavorable disease outcome, similar to
what is observed in other cancers [41]. The GO analysis
indicated that HDAC4 expression is functionally related to
the maintenance of chromosome structure. Meanwhile,
several previous studies have demonstrated various roles
for HDAC4 in cancer cells. In chondrosarcoma, a decrease
in HDAC4 expression leads to the upregulation of vascular
endothelial growth factor expression, thereby stimulating
angiogenesis [42]; in prostate cancer cells, HDAC4
downregulation was associated with a high level of
androgen receptor expression, which promoted cell growth
[43]. The results of the present study reveal that HDAC4 is
a strong prognostic factor in glioma and likely determines
patient outcome via modulation of genomic integrity.
The most widely used marker of genomic instability is
the CIN signature, which embodies aberrations in chro-
mosome number as well as structure [44]. There was
considerable overlap in the CIN25 score across tumor
grades, and patients with the same grade had significantly
different CIN25 scores. The overlap between grades was
normalized by restricting the analysis of CIN25 score to
each grade in the glioma databases; as in the case of other
cancers, a higher score was linked to high pathological
grade and unfavorable prognosis, confirming that a loss of
genomic integrity plays an important role in tumorigenesis
and impacts patient prognosis. The strongly negative cor-
relation between HDAC4 expression and CIN which
determined by statistical analyses of GO results and by
GSEA confirmed the utility of HDAC4 as a more conve-
nient, alternative marker of genomic instability.
Previous studies have reported that cancer cells with a
high degree of CIN acquire multi-drug resistance at higher
rates as compared to diploid cells with stable chromo-
somes. This is true in the case of colorectal cancer,
regardless of somatic mutation status [45]. A similar rela-
tionship to drug sensitivity was found in soft tissue sar-
coma and ovarian cancer [32, 46]. In this study, GBM
patients with a low CIN25 score were more sensitive to
radiochemotherapy and lived longer than those receiving
radiotherapy alone, but there were no differences observed
between the two treatment groups for patients with a high
CIN25 score. The relationship between CIN and multi-drug
resistance can be explained by the increased heterogeneity
in malignant cancers resulting from CIN, which increases
the probability of a drug-resistant subclone arising in the
tumor [47].
Combined radiochemotherapy, rather than radiotherapy
or chemotherapy alone, is a standard treatment for GBM.
MGMT promoter methylation status is a clinical predictor
of the extent to which GBM patients will benefit from
chemotherapy [25]. Several studies have shown that
MGMT deficiency resulting from MGMT promoter meth-
ylation may confer increased sensitivity to alkylating
Fig. 4 Association between
HDAC4 expression and CIN25
in glioma. HDAC4 expression
level was closely correlated
with CIN25 score in the CGGA
(a) and other validation sets (b,
c). The GSEA showed that
CIN25 genes were significantly
enriched in samples with low
HDAC4 expression (d). The
horizontal bar in graded color
from red to blue represents the
rank ordering of patients based
on increasing HDAC4
expression. The vertical black
lines represent the projection of
individual genes constituting the
CIN25 score. Genes on the left
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agents, yet some glioma patients with MGMT promoter
methylation still exhibit resistance to these drugs [25, 48].
Thus, evaluating genomic integrity in combination with
MGMT promoter methylation status may provide addi-
tional insight into the mechanism underlying the acquisi-
tion of drug resistance [49]. The current analysis of GBM
patients with MGMT promoter methylation receiving
combined radiochemotherapy revealed that survival was
prolonged in patients with a low CIN25 score (indicating a
more stable genome) than those with a high score; in the
latter group, the poor outcome was likely due in part to
chemotherapy resistance arising from increased CIN.
These results indicate that the sensitivity to chemotherapy
conferred by MGMT methylation depends on a stable
genome, and that the degree of genomic instability further
stratifies patients with MGMT methylation. The CIN25
score encompasses the status of 25 different genes, and as
such, is difficult to incorporate into routine clinical practice
as a diagnostic tool. Based on the strong association
between HDAC4 expression and CIN, we examined whe-
ther the combination of MGMT promoter methylation sta-
tus and HDAC4 expression level could instead be used to
predict patient outcome. Interestingly, for the highly
malignant GBM, combined radiochemotherapy had the
greatest benefit for patients with MGMT promoter meth-
ylation and high HDAC4 expression (indicating a lesser
degree of CIN). Thus, these two factors combined can
identify patients with the best prognosis who are suitable
candidates for more aggressive therapy, even the underly-
ing mechanisms needed further experimental methods for
interpretation.
Such an analysis helped us gain a novel perspective for
understanding the chemotherapy resistance in GBM patients.
The mechanisms of chemotherapy resistance resulted from
CIN needed further experimental methods for interpretation.
In addition, whether the CIN degree was a determining factor
in gliomagenesis of different subtypes and further tightly
associated with the appearance of MGMT promoter methyl-
ation in GBM patients were pertinent questions as well. With
immunohistochemistry being widely used in both routine
clinical practice and research, the role of HDAC4 in glioma
could be further validated from protein level in the near future.
Clinically, our next major goal is to verify its role in the
guidance of glioma diagnosis and treatment.
In conclusion, in present study, HDAC4 expression was
found to be closely related to tumor grade and patient
prognosis, and functional and statistical analyses identified
a correlation between HDAC4 expression and CIN signa-
ture in glioma. Taken together, the results indicate that
HDAC4 can serve as a marker of CIN and, when combined
with MGMT promoter methylation status, may be used to
identify GBM patients who would benefit most from
combined radiochemotherapy.
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